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Objective: Arterial cell and gene therapies are promising strategies for the treatment of cardiovascular diseases; however,
the optimal cell type and delivery technique for such treatment remain to be determined. The aim of the present study was
to design a new approach for arterial cell and gene therapy in which genetically modified autologous skin fibroblasts are
percutaneously delivered in stented rabbit femoral arteries in vivo.
Methods: Autologous skin fibroblasts underwent in vitro transfection with the cationic lipid FuGene and plasmids
expressing the human form of the tissue inhibitor of metalloproteinase (hTIMP-1) or nls-LacZ reporter genes.
Result: Transfection efficiency was about 50% and there were high levels of hTIMP-1 secretion up to 14 days after gene
transfer. We demonstrated the feasibility of in vivo percutaneous transplantation of fluorescent fibroblasts in the rabbit
femoral artery. Results were confirmed by scanning electron microscopy. In vivo local delivery of hTIMP-1-expressing
fibroblasts in stented femoral arteries also resulted in high-levels of hTIMP-1 secretion ex vivo for 7 days. Fibroblast
transplantation resulted in a modest increase in intimal hyperplasia at the target site, which was reversed with
hTIMP-1-transfected fibroblasts.
Conclusion: Percutaneous transplantation of genetically modified autologous fibroblasts could be used as a cellular
platform for locoregional secretion of therapeutic proteins to treat either specific arterial diseases or the diseased organ
(eg, the heart) supplied by the target artery. ( J Vasc Surg 2006;44:1067-75.)
Clinical Relevance: Cell and gene therapies are potential new treatments for cardiovascular diseases. We demonstrated
that autologous fibroblasts could be easily harvested from a skin biopsy specimen, genetically modified in vitro with
nonviral vectors, and percutaneously seeded in vivo in rabbit femoral arteries, leading to locoregional secretion of
abundant amounts of recombinant proteins. This new approach has important advantages over alternative approaches
that use endothelial cells, viral vectors, and intraoperative cell delivery. Clinical applications may include local treatment
of atherosclerotic plaques or aneurysms and also treatment of the diseased organs supplied by the target artery (eg,
ischemic or failing heart).Arterial cell and gene therapies are promising strategies
for the treatment of a large range of diseases. The aim is to
treat locally a specific arterial disease such as atherosclero-
sis,1 restenosis,2-4 arteriovenous graft disease,5 aneurysms,6
or pulmonary hypertension,7 or, alternatively, use the tar-
get arterial site as a platform for local production of thera-
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doi:10.1016/j.jvs.2006.07.022peutic proteins such as angiogenic growth factors for myo-
cardial or peripheral therapeutic angiogenesis,8 inhibitors
of matrix metalloproteinases for prevention of left ventricle
remodeling and heart failure,9 or antineoplastic agents for
tumor suppression,10 which are systemically delivered by
the flowing blood to the diseased organ supplied by the
target artery.
In the local arterial cell therapy approach, in situ deliv-
ery of healthy, specific vascular cells to replace the native
dysfunctional cells has been accomplished with endothelial
or endothelial progenitor cells11,12 or vascular smooth
muscle cells.3,6,13 In the locoregional arterial cell therapy
approach, the transplanted cell type is less crucial to the
success of the treatment, provided that it can be easily
harvested in large numbers, rapidly grown using standard
methods, genetically modified in vitro, and injected in the
target artery with sufficient engraftment capacity to secrete
abundant amounts of therapeutic proteins.
For both approaches, however, the optimal cell type
and cell delivery techniques for arterial cell therapy remain
to be determined. The aim of the present study was to
1067
JOURNAL OF VASCULAR SURGERY
November 20061068 Mazighi et aldesign a new approach for arterial cell and gene therapy in
which genetically modified, autologous skin fibroblasts
were percutaneously delivered into stented rabbit femoral
arteries in vivo. The efficacy of in vitro transfection of
fibroblasts using nonviral vectors, fibroblast engraftment in
the arterial wall, local arterial wall response to fibroblast
transplantation, and the time-course of transgene expres-
sion ex vivo were studied. The tissue inhibitor of metallo-
proteinase (TIMP)-1 gene, a potential candidate for gene
therapy for heart failure,9 restenosis,14 atherosclerotic
plaque rupture,15 or aneurysm formation13 was used as a
reporter gene for fibroblast transfection.
METHODS
Cell culture and transfection. To document trans-
fection efficiency and the time-course of transgene expres-
sion, rabbit fibroblasts were obtained from a primary cul-
ture of 2-cm2 skin samples of five different animals, as
described.16 Cells were grown in Dulbecco Modified Ea-
gle’s Medium (DMEM) (BioMedia, Foster City, Calif),
with serum, at 37°C in humidified 5% carbon dioxide/95%
air. No contamination of cell culture occurred. Immuno-
stainings with monoclonal antibodies against smooth mus-
cle -actin (dilution 1:50; Enzo Diagnostics, Farmingale,
NY), CD31 (dilution 1:50; Dako, Glostrup, Denmark) and
RAM-11 (dilution 1:50; Dako) found no smooth muscle
cells, endothelial cells, or macrophages in cell culture,
which therefore contained exclusively fibroblasts.
Five million fibroblasts were obtained in 2 to 3 weeks
and used at passage two or three and at 60% to 70% con-
fluence for in vitro transfection. Fibroblasts were incu-
bated overnight with plasmid open reading frames (pORF)-
TIMP-1 plasmid (Invivogen, San Diego, Calif), expressing
the human form of TIMP-1 (hTIMP-1) under the control
of the EF-1/HTLV promoter; pORF-nls-LacZ plasmid,
encoding a nuclear -galactosidase under the control of the
same promoter; or with DMEM alone. The nonliposomal,
cationic lipid FuGene (Roche Molecular Biochemicals,
Mannheim, Germany) was used as transfectant (DNA/
FuGene ratio 2:1), as described.17,18
The culture medium without serum was daily replaced,
collected at 1, 2, 3, 7, 14, 21, and 28 days after transfection,
and stored at 20°C. The hTIMP-1 concentration was
measured in the conditioned culture medium using an
enzyme-linked immunoabsorbent assay (ELISA) kit (R&D
Systems, Minneapolis, Minn), which does not cross-react
with rabbit TIMP-1 (detection threshold  0.030 ng/
mL). Cellular -galactosidase activity was assessed by X-gal
(Boehringer Mannheim Corp, Indianapolis, Ind) staining
at the same time points, as described.19 The time point at
which the highest transgene expression levels and percent-
age of transfected cells were observed was used subse-
quently in cell transplantation studies.
In vivo fibroblast seeding in balloon-injured femo-
ral arteries. The animal protocols were approved by the
Bichat University Institutional Animal Care and Use Com-
mittee. Autologous fibroblasts were fluoro-labeled in vitro
with PKH 26 (Sigma, St Louis, Mo), as described.20 ElevenNew ZealandWhite rabbits (3.5 to 4 kg) were anesthetized
with intravenous pentobarbital, a 5F sheath was introduced
in the right carotid artery, and digital iliofemoral angiogra-
phy was performed using a dedicated fluoroscope (BV
Endura, Philips, Bothell, Wash).
A target arterial segment without angiographically vis-
ible side branches was carefully selected in the femoral artery
to limit cell loss in the blood stream upon cell transplantation
(Fig 1). Bilateral femoral artery balloon abrasion (3-mm
balloon diameter, three inflations at 10 atm for 30 seconds)
was performed to expose the subendothelial layers. This
was followed immediately by local delivery of 5.106 PKH
26-stained autologous fibroblasts suspended in 300 L
DMEM (8 right femoral arteries), or DMEM alone (8 left
femoral arteries), using a Dispatch catheter (Boston Sci-
entific Scimed, Natick, Mass; Fig 2) inflated at 8 atm, as
described.21 The infusion lumen dead space was flushed
with 400 LDMEM to ensure proper fibroblast delivery in
the cell transplantation chambers delineated by the inflated
spiral coil.
Cells were allowed to dwell for 15 minutes, and then
nonengrafted fibroblasts were aspirated back into the cath-
eter infusion lumen before coil deflation and catheter re-
trieval. This incubation time was determined in preliminary
experiments, in which no fibroblast engraftment was doc-
umented after a 5-minute incubation, and a similar number
of fibroblasts were found after 15-minute or 30-minute
incubations (data not shown). Animals were euthanized by
pentobarbital overdose 1 hour after cell seeding.
In six rabbits, two 5-mm-long arterial rings taken from
the center of the target arterial segment were cryopreserved
in liquid nitrogen-frozen isopentane, and three 4-m-thick
arterial cross-sections were obtained from each ring and
Fig 1. Digital angiogram of the rabbit iliofemoral arteries before
percutaneous local delivery of autologous fibroblasts. Note that
care was taken to select a target arterial segment (between black
arrowheads) without angiographically visible side branches to limit
fibroblast loss during local delivery.examined under a fluorescence microscope for qualitative
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obtained from the gastrocnemius muscle (located below-
knee) of the treated hind limbs to assess the distal spread
of non-engrafted fibroblasts. Muscles were cryopreserved,
and 4-m-thick sections were obtained and examined as
above. The presence of red fluorescence in these distal
muscles indicated distal fibroblast spread.
A quantitative study of the total number of fibro-
blasts engrafted at the surface of the balloon-injured
femoral arteries was performed in three rabbits. Arteries
were harvested 1 hour after in vivo local delivery of 5.106
nontransfected fibroblasts or DMEMalone (15-minute incu-
bation), fixed in paraformaldehyde, mounted on a slide,
stained with hematoxylin, and observed en face under a
light microscope. Hematoxylin-stained nuclei were counted
on 20-fields encompassing the entire arterial surface us-
ing the Histolab software (Microvision Instruments, Evry,
France).
Fibroblast engraftment was assessed in two rabbits by
using canning electron microscopy (SEM 420, LEO Elec-
tron Microscopy Ltd, Cambridgeshire, UK). Arterial sam-
ples were prepared and observed over the entire length at
the specified magnifications, as described.22
Cell seeding with genetically modified fibroblasts in
stented femoral arteries. Autologous fibroblasts were
seeded in stented femoral arteries. The rationale for stent
implantation before cell seeding was that balloon injury
associated with cell transplantation procedures per se may
induce luminal narrowing due to negative remodeling of
the arterial wall or intimal hyperplasia, or both,23 which
may be prevented by stenting.
Localization of transplanted fibroblasts. In vitro
transfection of autologous fibroblasts was performed 72
hours before cell transplantation. Three rabbits underwent
bilateral femoral artery stenting (3-mm diameter, 18-mm
length; 30 s inflation at 8 atm)withMultilinkTetra (Guidant,
Fig 2. The Dispatch catheter used for cell transplantation incor-
porates a 20-mm-long  3-mm-diameter spiral inflation coil
wrapped around an urethane sheath covered by a layer of 24
perforated channels, each with a single 100-m infusion opening
through which cells are delivered via an independent infusion
lumen.Rueil Malmaison, France) in vivo before local delivery intwo arteries each of 5.106 nls-LacZ-transfected or non-
transfected autologous fibroblasts, or DMEM alone, using
the Dispatch catheter. Femoral arteries were explanted 1
hour after cell seeding, fixed in 4% paraformaldehyde,
stained in X-gal for 4 hours at 37°C, opened longitudinally,
and photographed en face under a dissecting microscope
before and after removal of stent struts. The total number
of dark blue dots, representing clusters of nls-LacZ-
expressing fibroblasts, was counted over the entire length
of the target arterial segment after removal of stent struts.
Time-course of hTIMP-1 secretion. Bilateral femo-
ral artery stenting was done in 24 rabbits before local
delivery of 5.106 autologous fibroblasts (hTIMP-1-trans-
fected, nls-LacZ-transfected, or nontransfected) or
DMEM alone (n  12 arteries in each group). In all
experiments, transfection efficiency (measured by the per-
centage of fibroblasts expressing nls-LacZ or the concen-
tration of secreted hTIMP-1) was measured before trans-
plantation. Transfection efficiency of 35% (nls-LacZ
transfection) or 1000 ng/mL (hTIMP-1 transfection)
was a prerequirement for cell transplantation. One hour
after fibroblast transplantation, femoral arteries were ex-
planted, flushed with ice-cold saline, and incubated for 28
days in 1 mL of DMEM, without serum, at 37°C in
humidified 5% carbon dioxide/95% air. The conditioned
culture medium was replaced daily, collected at 1, 2, 3, 7,
14, 21, and 28 days, and stored at 20°C until hTIMP-1
measurement (ELISA). Results were expressed as hTIMP-1
concentration in the conditioned culture medium normal-
ized to the tissue wet weight.
Local effect of fibroblast transplantation on intimal
growth. Twelve rabbits underwent bilateral femoral artery
stenting, followed by local delivery of 5.106 autologous
fibroblasts (hTIMP-1-transfected, nls-LacZ-transfected, or
nontransfected) or DMEM alone (n  6 arteries in each
group). Rabbits were euthanized 28 days after fibroblast
transplantation, and the femoral arteries were perfusion-
fixed at physiologic pressure with 4% paraformaldehyde,
embedded in 80% methyl methacrylate/20% dibutyl
phthalate, and processed for morphometric analysis, as
described.24 For each artery, four 4-m cross-sections were
obtained from the proximal, mid-proximal, mid-distal, and
distal segments and analyzed using theHistolab software to
study neointima formation at the cell transplantation site.
Statistical analysis. Data are expressed as mean SD.
The hTIMP-1 concentrations over time and morpho-
metric data 28 days after fibroblast transplantation were
compared using repeated measures and one-factor analysis
of variance, respectively, with Fisher’s protected least sig-
nificance difference post hoc tests (Statview 5.0, SAS Insti-
tute Inc, Cary, NC). A value of P 	 .05 was considered
significant.
RESULTS
Transfection of rabbit fibroblasts in vitro. The
time-course of the hTIMP-1 concentration in the condi-
tioned culture medium of hTIMP-1-transfected fibroblasts
is shown in Fig 3, A. The hTIMP-1 concentration peaked
cation
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remained detectable for at least 21 days. No hTIMP-1
expression was found in the conditioned culture medium of
nls-LacZ-transfected or nontransfected fibroblasts.
A similar time-course was observed for nls-LacZ gene
expression (Fig 3, B). The percentage of nls-LacZ-positive
fibroblasts was maximal 3 days after transfection (41% 
5.1%) and then decreased. No nls-LacZ activity was
found in hTIMP-1–transfected or nontransfected fibro-
blasts (Fig 3, B).
On the basis of these results, autologous fibroblasts
used for transplantation studies were transfected 72 hours
before cell transplantation to achieve optimal transgene
expression at the time of cell transplantation.
Microscopic examination of in vivo fibroblast seed-
ing in balloon-injured femoral arteries. An en face ex-
amination with a light microscope showed the presence of
foci of hematoxylin-stained nuclei over the luminal aspect
of injured arteries incubated with fibroblasts (56,500 
13,435 cells/artery). The absence of such pattern in arter-
ies incubated with DMEM alone suggests that cells present
at the surface of arteries incubated with fibroblasts are
Fig 3. Transfection of autologous rabbit skin fibrobla
metalloproteinase 1 (hTIMP-1) and nls-LacZ protein sec
concentration in the conditioned medium. B, The per
transfection, then decreased but remained detectable up
indicate hTIMP-1-transfected, nls-LacZ-transfected, and
Results represent the means of five experiments and ar
nls-LacZ-transfected cultured fibroblasts. Blue nuclei ind
500). D, Nontransfected cultured fibroblasts (magnifiengrafted fibroblasts.On fluorescence microscopy, randomly spaced foci
of red fluorescence were visible in 30 of 36 examined
femoral artery cross-sections after local delivery of PKH-
26-fluoro–labeled fibroblasts (Fig 4, A). No red fluores-
cence was observed in femoral arteries treated with DMEM
alone (Fig 4, B) or in distal hind-limb muscles.
Scanning electron microscopy analysis of femoral arter-
ies incubated with fibroblasts revealed the presence of
clustered, round, adherent cells, entrapped in a dense fibrin
mesh. These were not present in control arteries incubated
with DMEM alone, and, hence, were considered as en-
grafted fibroblasts (Fig 4, C and D).
In vivo cell seeding with genetically modified fibro-
blasts in stented femoral arteries.
Localization of transplanted cells. X-gal-staining of
femoral arteries incubated in vivo with nls-LacZ-
transfected fibroblasts revealed clusters (70  20 clusters/
artery) of nls-LacZ-positive fibroblasts (Fig 5). No nls-
LacZ expression was found in femoral arteries incubated
with nontransfected fibroblasts or DMEM alone. Some
levels of arterial necrosis, assessed by measurement of lac-
vitro. A-B, Time-course of human tissue inhibitor of
after FuGene-mediated transfection. A, The hTIMP-1
ge of nls-LacZ-positive fibroblasts peaked 3 days after
days. Black diamonds, white triangles, and black squares
-transfected fibroblasts, respectively. *P	 .05 vs days 0.
ressed as means  SD. C, Representative example of
nls-LacZ gene expression (X-gal staining) (magnification
500).sts in
retion
centa
to 21
non
e exp
icatetate dehydrogenase (LDH) in the culture media, were
platel
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vary overtime and were similar in the 4 groups (data not
shown).
Kinetics of hTIMP-1 secretion after in vivo cell seeding
with hTIMP-1-transfected fibroblasts. Detectable levels of
hTIMP-1 were found in the conditioned culture medium
of femoral arteries incubatedwith hTIMP-1-transfected fibro-
blasts but not in arteries incubated with nls-LacZ-transfected
fibroblasts, nontransfected fibroblasts, or DMEM alone.
The hTIMP-1 concentration peaked 3 days after cell trans-
plantation, then decreased by 90% at 14 days, and was
undetectable at 28 days (Fig 5).
Intimal growth at the stented arterial site after fibro-
blast transplantation. At 28 days after stent implantation,
in-stent intimal area, intima/media ratio, and luminal area
narrowing were slightly, but significantly, larger in femoral
arteries incubated with nontransfected or nls-LacZ-
Fig 4. In vivo percutaneous transplantation of autologo
Fluorescence microscopy detected fluorescent fibroblast
arterial segment 1 hour after local cell delivery with the D
control femoral artery incubated with Dulbecco Modifi
20 magnification). C, Scanning electron microscopy sh
fibrin (F), and red blood cells (RBC) are visible at th
fibroblasts,D, but not in the control artery incubated with
in the control artery unmasks the presence of abundanttransfected fibroblasts than in femoral arteries incubatedwith DMEM alone (Table). This adverse effect of fibroblast
transplantation on neointimal growth, however, was re-
versed after transplantation of hTIMP-1-transfected fibro-
blasts (no difference vs DMEM alone for the three studied
parameters).
DISCUSSION
In the present study, we demonstrated the feasibility of
in vivo percutaneous transplantation of nonvirally trans-
fected, autologous fibroblasts in the rabbit femoral artery.
Previous experimental studies of cell transplantation in the
arterial wall used intraoperative techniques.25-28 The main
advantage of the intraoperative approach is that cell delivery
is performed in tightly controlled conditions, resulting in
high cell engraftment efficiency. The principal drawbacks of
this approach are that it requires a potentially hazardous
roblasts in the balloon-injured rabbit femoral artery. A,
ite arrowheads) along the luminal border of the target
tch catheter. B, Note the absence of fluorescence in the
agle’s Medium (DMEM) alone (original magnification
foci of round fibroblasts (Fibro) entrapped in a mesh of
face of the femoral artery incubated with autologous
EM alone. Note that the absence of engrafted fibroblasts
ets (P) at the balloon-injured site.us fib
s (wh
ispa
ed E
ows
e sur
DMsurgical procedure and flow interruption. In contrast with
terial
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proach for cell transplantation.
The Dispatch catheter is particularly suitable for arterial
cell delivery because its infusion pores are large enough to
accommodate all candidate cell types and its coiled feature
allows for close contact between the cells and the arterial
wall while blood flow is maintained through the central
lumen.21 The Dispatch catheter also allows non-engrafted
cells to be aspirated back into the infusion lumen, a feature
Fig 5. In vivo percutaneous transplantation of geneti
femoral artery. A, Time course of ex vivo human tissue i
in stented arteries incubated in vivo with hTIMP-1-tran
gles), or nontransfected (black squares) fibroblasts, or wit
in the conditioned medium of arteries incubated with h
transplantation, then decreased by 90% at 14 days and w
other groups. Results were normalized to the tissue wet
Data are expressed as means  SD. *P 	 .05 vs days 0. B
engrafted at the surface of stented femoral arteries. Arte
40 magnification) and after (C; original magnification
nls-LacZ-positive fibroblasts (black arrowheads) at the arthat may limit systemic cell spread after catheter removal.Indeed, in the present study, no transplanted fibroblasts
were found in distal (below-knee) muscles of rabbit hind
limbs after cell delivery, whereas such cell dissemination has
been reported in a previous study in which transfected
fibroblasts were injected systematically.21,29
Several mechanisms are likely to concur with the lower
transplantation efficiency of percutaneous vs intraoperative
cell delivery,26,30 including cell leakage in the distal run-off,
due to suboptimal apposition of the catheter coil to the
modified autologous fibroblasts in the stented rabbit
tor of metalloproteinase 1 (hTIMP-1) protein secretion
d (black diamonds), nls-LacZ-transfected (white trian-
EM alone (white squares). The hTIMP-1 concentration
-1-transfected fibroblasts peaked 3 days after fibroblast
ndetectable at 28 days. It was not detected in the three
t and represent the means of 12 arteries in each group.
Representative examples of nls-LacZ-positive fibroblasts
ere examined en face before (B; original magnification
removal of stent struts. Note the presence of clusters of
surface.cally
nhibi
sfecte
h DM
TIMP
as u
weigh
-C,
ries w
10)arterial wall, or through collateral branches, this latter issue
ts.
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than in the carotid artery.2,3,27,31 Another potential mech-
anism is that cells may be harmed by traveling through the
catheter lumen; however, we did not find reduced fibro-
blast viability in preliminary experiments performed with
Trypan Blue exclusion tests on fibroblasts effluxing from
the infusion pores of the inflated Dispatch catheter (data
not shown).
Several previous studies of cell transplantation in the
arterial wall have been performed with endothelial (or
endothelial progenitor) cells,27,31,32 based on the rationale
that these cells would mitigate intimal growth and prevent
arterial thrombosis; however, the ability of exogenous en-
dothelial and endothelial progenitor cells to inhibit intimal
hyperplasia is controversial.30,33 Moreover, autologous en-
dothelial and endothelial progenitor cells are available in
only minute amounts in vascular or blood samples and
require prolonged and complex cell culture techniques. In
addition, recent studies suggest that exogenous endothelial
cells have a limited ability to adhere to balloon-injured rat
aortas,26 whereas others documented both endothelial cell
engraftment and inhibition of intimal growth.27
Vascular smooth muscle cells are available in larger
amounts in vascular samples and can be efficiently grafted
on rat balloon-injured aortas26 or aortic xenografts.6 Both
nongenetically modified6,26 and genetically modified 2,23
vascular smooth muscle cells have been shown to inhibit
intimal growth and prevent aneurysm rupture in experi-
mental models. In these studies, however, a syngenic model
of cell transplantation was used, allowing for use of large
numbers of vascular smooth muscle cells pooled from
different animals, a technique that is likely to mount an
immune response against transplanted cells in larger ani-
mals or in humans. The combined necessity to use autolo-
gous cells that can be easily harvested in large numbers
using a minimally invasive procedure was the incentive to
use skin fibroblasts in the present study. Indeed, starting
from a 2-cm2 skin sample, we were able to obtain about
5.106 autologous fibroblasts within 2 to 3 weeks using
standard cell culture techniques.
Nonviral transfection of fibroblasts with FuGene-plas-
mid complexes resulted in approximately 50% transfection
efficiency and high levels of hTIMP-1 secretion for 7 days,
followed by low-level hTIMP-1 secretion up to 21 days.
Table I. Intimal growth parameters after in vivo percutan
Intimal area (mm2) Me
DMEM alone 1.89  0.8
Non-transfected fibroblasts 2.80  1.6*†
nls-LacZ-transfected fibroblasts 2.77  1.6*†
hTIMP-1–transfected fibroblasts 1.94  1.3
DMEM, Dulbecco Modified Eagle’s Medium; hTIMP-1, human form of tis
Results represent the means of six arteries in each group.
*P 	 .05 vs DMEM alone.
†P 	 0.05 vs non-transfected fibroblasts and nls-LacZ-transfected fibroblasKinetics of hTIMP-1 secretion did not relate to arterialtoxicity, as assessed by measurement of LDH levels in the
culture media (data not shown). Retroviral vectors have been
used in numerous arterial cell therapy studies 2,3,13,28,30 be-
cause of their high transfection efficiency in vitro and their
ability to integrate in the host cell genome, thus allowing
for protracted transgene expression; however, clinical haz-
ards associated with the use of retroviral vectors have been
recently underlined.34 Ishii et al,29 used an adenoviral
vector for fibroblast transfection, the safety of which has
also been questioned.35
In the present study, we chose to perform fibroblast
seeding in a stented arterial segment with the rationale that
local delivery procedures and the high biosynthetic activity
of fibroblasts may both induce negative vessel remodeling
(reduction in external vessel diameter) and intimal growth,
resulting in luminal narrowing that may be prevented by
stenting. Indeed, transplantation of autologous fibroblasts
in stented rabbit femoral arteries resulted in a modest,
albeit significant, increase in intimal hyperplasia and lumi-
nal narrowing at the target site.
This observation is in keeping with previous studies of
intraoperative transplantation of syngenic fibroblasts in the
rat aorta, in which intimal growth associated with fibroblast
transplantation resulted predominantly from a twofold in-
crease of intimal collagen density.26 In this regard, our
coincidental finding that intimal growth after transplanta-
tion of hTIMP-1-expressing fibroblasts is reduced (and not
different from the intimal growth induced by stenting and
sham local delivery procedure) may be reminiscent of the
beneficial effect of synthetic matrix metalloproteinase in-
hibitors on in-stent collagen accumulation.36 Alternatively,
hTIMP-1 overexpressionmaymitigate vascular smooth cell
proliferation.37 Long-term follow-up experiments are re-
quired to address the stability of the observed effect on
intimal growth. Development of new local delivery cathe-
ters with higher cell transplantation efficiency and lower
traumatic effect of the arterial wall is also mandatory.
Still, prevention of in-stent restenosis, which can now
be efficiently achieved with drug-eluting stents,38 does not
seem to be an appropriate target for fibroblast-based cell
and gene therapy. In contrast, the phenotype of aneurysms
or vulnerable atherosclerotic plaques may be positively
altered by the combination of in situ collagen accumulation
and therapeutic gene expression. Fibroblasts could also be
transplantation of autologous fibroblasts
rea (mm2) Intima/media ratio Luminal narrowing (%)
 0.1 6.30  0.5 67.6  3.0
 0.1 7.17  0.6*† 84.7  4.4*†
 0.1 7.10  0.6*† 84.6  4.4*†
 0.1 5.39  0.4 68.2  3.0
hibitor of tissue inhibitor of metalloproteinase 1.eous
dial a
0.30
0.39
0.39
0.36
sue inused as a cellular platform for locoregional secretion of
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taneous transplantation of genetically modified fibroblasts
in coronary arteries may increase local concentrations of
proangiogenic growth factors or inhibitors of left ventricle
remodeling in the distal run-off of the target artery, and
hence represents an alternative treatment for the ischemic
or failing heart. Further studies are required to fully appre-
ciate the utility of fibroblast-based cell and gene therapy in
cardiovascular diseases.
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November 20061075.e1 Mazighi et alFig e1 (online only). En face view of hematoxylin-stained femoral arteries engrafted with DulbeccoModified Eagle’s
Medium (DMEM) (A) or fibroblasts (B). Note the presence of foci of hematoxylin-stained nuclei (black arrowheads)
over the luminal aspect of the artery only after fibroblast delivery (B). The absence of such pattern in arteries incubated
with DMEM alone (A) suggests that cells present at the surface of the artery incubated with fibroblasts are engrafted
fibroblasts (original magnification 20).
Fig e2 (online only). Bar graph shows lactate dehydrogenase (LDH) dosage (expressed in optical density units) in the
conditioned culture media of rabbit femoral arteries incubated with Dulbecco Modified Eagle’s Medium (DMEM)
(black bars), nontransfected fibroblasts (hatched bars), nls-LacZ-transfected fibroblasts (grey bars) or hTIMP-1–
transfected fibroblasts (white bars) (n  6 in each group). Data are expressed as mean  SD.
Fig e3 (online only). Scatter graph shows the relationship between human tissue inhibitor of metalloproteinase 1
(hTIMP-1) concentration and intimal growth. No correlation between hTIMP-1 and intima/media ratio was
observed (n  6).
